VEDOKIDS study: Predicting response to Vedolizumab in Pediatric Inflammatory Bowel Diseases including drug levels: a multi-center prospective Pan- European cohort study (P-ECCO and ESPGHAN)

Go Back to All Clinical Trials

VEDOKIDS study: Predicting response to Vedolizumab in Pediatric Inflammatory Bowel Diseases including drug levels: a multi-center prospective Pan- European cohort study (P-ECCO and ESPGHAN)

Brief description of study

The purpose of this research study is to learn more about a medication used to treat crohns and ulcerative colitis. Subjects are invited to participate in this study if they are going to be taking vedolizumab, a monoclonal antibody for the treatment of their Crohns disease or Ulcerative colitis to induce and maintain remission of the disease. Vedolizumab is FDA approved for use in adults and children. However, more information is needed to understand children’s responses to the drug.

Clinical Study Identifier: s19-00523

ClinicalTrials.gov Identifier: NCT02862132

Principal Investigator: Jeremiah Levine.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies